| Grant number: | 24/16992-7 |
| Support Opportunities: | Regular Research Grants |
| Start date: | February 01, 2025 |
| End date: | January 31, 2028 |
| Field of knowledge: | Biological Sciences - Physiology - Physiology of Organs and Systems |
| Principal Investigator: | Norberto Garcia Cairasco |
| Grantee: | Norberto Garcia Cairasco |
| Host Institution: | Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil |
| Associated researchers: | Adriano Silva Sebollela ; Bruno Antonio Benitez Viloria ; Christian Andrés Rojas Cerón ; Eduardo Rigon Zimmer ; Efraín Buriticá Ramirez ; Guilherme Gozzoli Podolsky Gondim ; Lina Vanessa Becerra Hernández ; Maria Elisa Calcagnotto ; Mark Oliver Cunningham |
Abstract
Alzheimer's disease (AD), the most common type of dementia and the fourth leading cause of disability among people aged 75 and over, is a progressive neurodegenerative condition. It impairs memory and language and causes behavioral/psychiatric changes. Evidence from the literature and from the Laboratory of Neurophysiology and Experimental Neuroethology (LNNE), with experience in epilepsy/neuropsychiatric comorbidities, suggests central insulin resistance (CIR) and alterations in the insulin signaling pathway (VSI) as a bidirectional link between AD and epilepsy. There is clinical evidence of alterations in the VSI in patients with AD, but no evidence of alterations in the VSI in individuals with epilepsy. In this context, the LNNE demonstrated: (1) In the Wistar Audiogenic Rat (WAR) genetic model of epilepsy, there is spatial memory impairment/hyperphosphorylation of tau protein, and alterations in the VSI. (2) Streptozotocin (STZ; mimics diabetes and AD) predisposes to seizures. Antidiabetic drugs (e.g. metformin) attenuate the effects of STZ, and the mechanisms in the CNS are unknown. Therefore, understanding the processes by which STZ acts, and how antidiabetic drugs can control them, will clarify the link between AD, ICR and epilepsy.We propose: (1) To evaluate a model of AD, by icv-STZ (promoter of neural hyperexcitability). (2) To analyze the effects of icv-STZ administration (WARs) and verify the exacerbation of the partial phenotype of AD and audiogenic seizures, by altering the regulation of VSI proteins. (3) To verify whether chronic treatment with metformin in WARs attenuates the partial phenotype of AD and seizures. (4) To evaluate cerebral glucose metabolism by microPET in Sprague-Dawley rats and WARs, after icv-STZ. (5) Verify whether brain tissues (surgeries from patients with epilepsy) present alterations in the VSI, versus post-mortem tissues from patients with AD. (6) Investigate the application of STZ in human organotypic cultures to study RCI, and its impact on AD and epilepsy. (7) Record electrophysiological activity in organotypic cultures (human epileptogenic zones), to detect hyperexcitability in vitro. (8) Perform transcriptomics/proteomics of brain from WARs/Wistar, and in human tissue from patients with epilepsy/controls, to recognize molecular signatures of the AD and epilepsy link. (AU)
| Articles published in Agência FAPESP Newsletter about the research grant: |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |